Paradoxical uptake of Gd-EOB-DTPA on the hepatobiliary phase in the evaluation of hepatic metastasis from breast cancer: Is the "target sign" a common finding?

Magnetic Resonance Imaging

Volumn 30, Issue 8, 2012, Pages 1083-1090

  Ha, Sumin ^a   Lee, Chang Hee ^a   Kim, Baek Hui ^a   Park, Yang Shin ^a   Lee, Jongmee ^a   Choi, Jae Woong ^a   Kim, Kyeong Ah ^a   Park, Cheol Min ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Breast cancer; Gadoxetic acid; Gd EOB DTPA; Liver; Metastasis; MRI

Indexed keywords

ANTINEOPLASTIC AGENT; GADOXETIC ACID;

ADULT; AGED; APPARENT DIFFUSION COEFFICIENT; ARTICLE; BREAST CANCER; CANCER PATIENT; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; DRUG UPTAKE; FEMALE; HEPATOBILIARY SYSTEM; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LIVER BIOPSY; LIVER METASTASIS; LIVER PARENCHYMA; MEDICAL RECORD REVIEW; METASTASIS SIZE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; ONCOLOGICAL PARAMETERS; PERCUTANEOUS BIOPSY; PHYSICAL PARAMETERS; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; RADIOLOGIST; RETROSPECTIVE STUDY; SIGNAL INTENSITY;

BREAST NEOPLASMS; CARCINOMA; FEMALE; GADOLINIUM DTPA; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

EID: 84866181072     PISSN: 0730725X     EISSN: 18735894     Source Type: Journal    
DOI: 10.1016/j.mri.2012.03.007     Document Type: Article

References (29)

1. Danet I.M., Semelka R.C., Leonardou P., et al. Spectrum of MRI appearances of untreated metastases of the liver. AJR Am J Roentgenol 2003, 181:809-817.
2. Atalay G., Biganzoli L., Renard F., et al. Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials. Eur J Cancer 2003, 39:2439-2449.
3. Whitlock J.P., Evans A.J., Jackson L., Chan S.Y., Robertson J.F. Imaging of metastatic breast cancer: distribution and radiological assessment at presentation. Clin Oncol (R Coll Radiol) 2001, 13:181-186.
4. O'Reilly S.M., Richards M.A., Rubens R.D. Liver metastases from breast cancer: the relationship between clinical, biochemical and pathological features and survival. Eur J Cancer 1990, 26:574-577.
5. Noone T.C., Semelka R.C., Balci N.C., Graham M.L. Common occurrence of benign liver lesions in patients with newly diagnosed breast cancer investigated by MRI for suspected liver metastases. J Magn Reson Imaging 1999, 10:165-169.
6. Huppertz A., Haraida S., Kraus A., et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT - initial observations. Radiology 2005, 234:468-478.
7. Tamada T., Ito K., Sone T., et al. Dynamic contrast-enhanced magnetic resonance imaging of abdominal solid organ and major vessel: comparison of enhancement effect between Gd-EOB-DTPA and Gd-DTPA. J Magn Reson Imaging 2009, 29:636-640.
8. van Montfoort J.E., Stieger B., Meijer D.K., Weinmann H.J., Meier P.J., Fattinger K.E. Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J Pharmacol Exp Ther 1999, 290:153-157.
9. Kanematsu M., Kondo H., Goshima S., et al. Imaging liver metastases: review and update. Eur J Radiol 2006, 58:217-228.
10. Choi J.Y., Choi J.S., Kim M.J., et al. Detection of hepatic hypovascular metastases: 3D gradient echo MRI using a hepatobiliary contrast agent. JMagn Reson Imaging 2010, 31:571-578.
11. Grazioli L., Morana G., Federle M.P., et al. Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine. Radiology 2001, 221:731-739.
12. Ringe K.I., Husarik D.B., Sirlin C.B., Merkle E.M. Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol 2010, 195:13-28.
13. Imam K., Bluemke D.A. MR imaging in the evaluation of hepatic metastases. Magn Reson Imaging Clin N Am 2000, 8:741-756.
14. Grazioli L., Morana G., Kirchin M.A., Schneider G. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 2005, 236:166-177.
15. Terayama N., Matsui O., Ueda K., et al. Peritumoral rim enhancement of liver metastasis: hemodynamics observed on single-level dynamic CT during hepatic arteriography and histopathologic correlation. J Comput Assist Tomogr 2002, 26:975-980.
16. Braga L., Semelka R.C., Pietrobon R., Martin D., de Barros N., Guller U. Does hypervascularity of liver metastases as detected on MRI predict disease progression in breast cancer patients?. AJR Am J Roentgenol 2004, 182:1207-1213.
17. Nino-Murcia M., Olcott E.W., Jeffrey R.B., Lamm R.L., Beaulieu C.F., Jain K.A. Focal liver lesions: pattern-based classification scheme for enhancement at arterial phase CT. Radiology 2000, 215:746-751.
18. Runge V.M.A. comparison of two MR hepatobiliary gadolinium chelates: Gd-BOPTA and Gd-EOB-DTPA. J Comput Assist Tomogr 1998, 22:643-650.
19. Bartolozzi C., Donati F., Cioni D., et al. Detection of colorectal liver metastases: a prospective multicenter trial comparing unenhanced MRI, MnDPDP-enhanced MRI, and spiral CT. Eur Radiol 2004, 14:14-20.
20. Kim Y.K., Lee J.M., Kim C.S., Chung G.H., Kim C.Y., Kim I.H. Detection of liver metastases: gadobenate dimeglumine-enhanced three-dimensional dynamic phases and one-hour delayed phase MR imaging versus superparamagnetic iron oxide-enhanced MR imaging. Eur Radiol 2005, 15:220-228.
21. Zech C.J., Herrmann K.A., Reiser M.F., Schoenberg S.O. MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA. Magn Reson Med Sci 2007, 6:43-52.
22. Petersein J., Spinazzi A., Giovagnoni A., et al. Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging - a multicenter phase III clinical study. Radiology 2000, 215:727-736.
23. Park M.S., Kim M.J., Lim J.S., et al. Metastasis versus focal eosinophilic infiltration of the liver in patients with extrahepatic abdominal cancer: an evaluation with gadobenate dimeglumine-enhanced magnetic resonance imaging. J Comput Assist Tomogr 2009, 33:119-124.
24. Kim Y.K., Lee J.M., Kim C.S. Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions. Eur Radiol 2004, 14:5-13.
25. Gabata T., Matsui O., Kadoya M., et al. Delayed MR imaging of the liver: correlation of delayed enhancement of hepatic tumors and pathologic appearance. Abdom Imaging 1998, 23:309-313.
26. Ba-Ssalamah A., Uffmann M., Saini S., Bastati N., Herold C., Schima W. Clinical value of MRI liver-specific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesions. Eur Radiol 2009, 19:342-357.
27. Lee S.A., Lee C.H., Jung W.Y., Lee J., Choi J.W., Kim K.A., et al. Paradoxical high signal intensity of hepatocellular carcinoma in the hepatobiliary phase of Gd-EOB-DTPA enhanced MRI: initial experience. Magn Reson Imaging 2011, 29:83-90.
28. Doo K.W., Lee C.H., Choi J.W., Lee J., Kim K.A., Park C.M. "Pseudo washout" sign in high-flow hepatic hemangioma on gadoxetic acid contrast-enhanced MRI mimicking hypervascular tumor. Am J Roentgenol 2009, 193:W490-W496.
29. Semelka R.C., Hussain S.M., Marcos H.B., Woosley J.T. Perilesional enhancement of hepatic metastases: correlation between MR imaging and histopathologic findings-initial observations. Radiology 2000, 215:89-94.